Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade

Stock Track

2025/11/14

Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.

The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.

According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1121303799"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121303799\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121303799?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121303799","market":"us","top_or_hot":-1,"title":"Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade","media":"Stock Track","content":"<p>Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.</p>\n\n<p>The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.</p>\n\n<p>According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.</p>\n\n<p>The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.</p>\n\n<p>According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"","article_id":"1121303799","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121303799","pubTimestamp":1763130781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics"},"translate_title":"个股追踪|Raymond James下调评级后Monopar Therapeutics暴跌7.48%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":1},"content_text":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.\nThe downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.\nAccording to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}